<DOC>
	<DOCNO>NCT00802568</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . PURPOSE : This phase II trial study side effect give fludarabine together busulfan antithymocyte globulin follow donor stem cell transplant see well work treat patient multiple myeloma respond treatment .</brief_summary>
	<brief_title>Fludarabine , Busulfan , Antithymocyte Globulin , Donor Stem Cell Transplant Treating Patients With Multiple Myeloma That Has Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - To study toxicity reduce intensity condition comprise fludarabine phosphate , busulfan , anti-thymocyte globulin follow allogeneic hematopoietic stem cell transplantation patient refractory relapse multiple myeloma . Secondary - To study tumor response patient . - To study incidence acute chronic graft-versus-host disease patient . - To study incidence infectious complication patient . - To study relapse- progression-free overall survival patient . - To study biological mechanism ( i.e. , take graft , immunological recovery , antitumor activity , chimerism ) . OUTLINE : This multicenter study . Patients receive reduce intensity condition comprise fludarabine IV day -5 -1 , oral busulfan day -4 -3 , anti-thymocyte globulin IV day -2 -1 . Patients undergo allogeneic hematopoietic stem cell transplantation day 0 . After completion study therapy , patient follow every month 6 month every 3 month 1Â½ year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma , meet 1 follow criterion : Stage I disease bone lesion Stage II III disease meeting follow criterion : Elevated beta2 microglobulin Deletion chromosome 13 Refractory relapse disease Presence evaluable monoclonal component Must achieve reduction primary tumor receive prior intensify chemotherapy highdose melphalan cyclosporine autologous transplantation HLA identical family donor available Bone marrow transplantation allow case hematopoietic stem cell collection fail PATIENT CHARACTERISTICS : Karnofsky 70100 % No contraindication allogeneic transplantation No contraindication drug use condition regimen No psychiatric illness No cancer within past 5 year except basal cell skin cancer epithelioma situ cervix No serious uncontrolled infection Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 1 month since participation another prior clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>osteolytic lesion multiple myeloma</keyword>
</DOC>